POPULATION-BASED OUTCOMES IN LARGE B-CELL LYMPHOMA BY WHO SUBTYPE: FINDINGS FROM THE UK'S HAEMATOLOGICAL MALIGNANCY RESEARCH NETWORK

2019 ◽  
Vol 37 ◽  
pp. 196-197
Author(s):  
R. Patmore ◽  
A. Smith ◽  
S. Barrans ◽  
D. Painter ◽  
D. Howell ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Haematological Malignancy ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Research Network ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Cell‐of‐origin in diffuse large B‐cell lymphoma: findings from theUK's population‐based Haematological Malignancy Research Network

2018 ◽  
Vol 185 (4) ◽  
pp. 781-784 ◽  
Author(s):  
Daniel Painter ◽  
Sharon Barrans ◽  
Stuart Lacy ◽  
Alexandra Smith ◽  
Simon Crouch ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Haematological Malignancy ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Research Network ◽  
Cell Of Origin ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sara Harrysson ◽  
Sandra Eloranta ◽  
Sara Ekberg ◽  
Gunilla Enblad ◽  
Mats Jerkeman ◽  
...  
Keyword(s):  
B Cell ◽  
Cumulative Incidence ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Refractory Disease ◽  
Curative Intent ◽  
Large B Cell Lymphoma ◽  
Cns Relapse ◽  
Large B Cell

AbstractWe performed a national population-based study of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in Sweden in 2007–2014 to assess treatment intent and risk of relapsed/refractory disease, including central nervous system (CNS) relapse, in the presence of competing risks. Overall, 84% of patients started treatment with curative intent (anthracycline-based) (n = 3550, median age 69 years), whereas 14% did not (n = 594, median age 84 years) (for 2% the intent was uncertain). Patients treated with curative intent had a 5-year OS of 65.3% (95% CI: 63.7–66.9). The median OS among non-curatively treated patients was 2.9 months. The 5-year cumulative incidence of relapsed/refractory disease in curative patients was 23.1% (95% CI: 21.7–24.6, n = 847). The 2-year cumulative incidence of CNS relapse was 3.0% (95% CI: 2.5–3.6, n = 118) overall, and 8.0% (95% CI: 6.0–10.6, n = 48) among patients with high CNS-IPI (4–6), when considering other relapse locations and death as competing events. The incidence of relapsed/refractory DLBCL overall and in the CNS was lower than in previous reports, still one in seven patients was not considered fit enough to start standard immunochemotherapy at diagnosis. These results are important for quantification of groups of DLBCL patients with poor prognosis requiring completely different types of interventions.

scholarly journals New nomograms based on treatment outcome and prognostic factors for patients with spinal diffuse large B-cell lymphoma: A population‐based study

2020 ◽  
Author(s):  
Ben Wang ◽  
Lijie Chen ◽  
Boda Chen ◽  
Chenglong Xie ◽  
Zhenxuan Shao ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Treatment Method ◽  
Population Based ◽  
Cancer Specific Survival ◽  
Internal Validation ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract Background: Spinal diffuse large B-cell lymphoma (DLBCL) was a rare and malignant tumor, while few studies researched the prognostic factors. The prognostic factors which might have impacts on spinal DLBCL was not clear. Although chemotherapy was recognized as an optimal treatment method, but the curative effect of radiotherapy and surgery were controversial. Methods: The records of patients with spinal DLBCL were selected from the SEER database from 1991 to 2016. The incidence obtained by database was analyzed by Joinpoint Regression Program. The optimal cut-off values of age and year of diagnosis were identified by X-tail program. Univariate and multivariate survival analysis were calculated to identify independent prognostic factors. Prognostic factors were included to predict the survival possibility compared with 5 years of overall (OS) and cancer-specific survival (CSS) via the new nomograms. Results: A total of 917 patients were enrolled. Age, year of diagnosis and chemotherapy were demonstrated as independent prognostic factors for CSS and OS, and primary site was another independent prognostic factor for CSS. However, radiotherapy and surgery might be ineffective in survival. All factors were included to generate the nomograms for CSS and OS. The concordance indices (C-index) for internal validation of OS and CSS prediction were 0.697 (95%CI: 0.662-0.732) and 0.709 (95%CI: 0.692- 0.727) respectively. Conclusions: Age and year of diagnosis are closely associated with the prognosis of spinal DLBCL, and chemotherapy is an ideal treatment modality. The new nomogram is a favourable tool to evaluate the survival possibility, and is benefit for the oncologist to make clinical decisions.

scholarly journals Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study

2019 ◽  
Vol Volume 11 ◽  
pp. 207-216 ◽  
Author(s):  
Bente Arboe ◽  
Maja Halgren Olsen ◽  
Jette Sønderskov Gørløv ◽  
Anne Katrine Duun-Henriksen ◽  
Susanne Oksbjerg Dalton ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Real Life ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Treatment Intensity ◽  
Population Based Study ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study

2013 ◽  
Vol 55 (3) ◽  
pp. 533-537 ◽  
Author(s):  
Cindy Varga ◽  
Christina Holcroft ◽  
Abbas Kezouh ◽  
Serghei Bucatel ◽  
Nathalie Johnson ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Population Based ◽  
80 And Over ◽  
Aged 80 And Over ◽  
Population Based Study ◽  
Younger Patients ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document